Zhongmu Co., Ltd. announced that the company acquired 51% of the shares of Hebei Shengxue Dacheng Pharmaceutical Co., Ltd. held by CNNC Uranium through public delisting, and 72.7272% of the shares of Inner Mongolia Shengxue Dacheng Pharmaceutical Co., Ltd. held by CNNC Uranium and other transferors, with a total transaction price of 727 million yuan. As of the announcement disclosure date, the equity settlement and industrial and commercial change registration procedures for this acquisition have been completed, and the company has become the controlling shareholder of the above two companies. This transaction will enhance the company's ability to be self-sufficient in veterinary drug raw materials, enrich the product matrix, and help expand overseas business.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.